Regorafenib for hepatocellular carcinoma progressing on sorafenib: just another starting point

Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide and a major global health problem. The incidence of HCC increases progressively with advancing age, reaching a peak at 70 years. Moreover, there is a growing incidence of HCC worldwide (1).